Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes

Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada

⁵

Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada

Author to whom correspondence should be addressed.

Academic Editors: Kenzo Tokunaga and Jérôme Estaquier

Viruses 2022, 14(1), 144; https://doi.org/10.3390/v14010144

Received: 13 December 2021 / Revised: 7 January 2022 / Accepted: 10 January 2022 / Published: 14 January 2022

(This article belongs to the Special Issue Basic Sciences for the Conquest of COVID-19)

View Full-Text Download PDF

Browse Figures

Review Reports Citation Export

Abstract

The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant. Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5. In this study, we observed that these Spike variants bound better to the ACE2 receptor in a temperature-dependent manner. Pseudoviral particles bearing the Spike of Mu were similarly neutralized by plasma from vaccinated individuals than those carrying the Beta (B.1.351) and Delta (B.1.617.2) Spikes. Altogether, our results indicate the importance of measuring critical parameters such as ACE2 interaction, plasma recognition and neutralization ability of each emerging variant. View Full-Text

Keywords: coronavirus; COVID-19; SARS-CoV-2; spike glycoproteins; RBD; ACE2; temperature; variants of concern; variants of interest; variants under monitoring; mRNA vaccines

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 286 KiB)

Share and Cite

MDPI and ACS Style

Chatterjee, D.; Tauzin, A.; Laumaea, A.; Gong, S.Y.; Bo, Y.; Guilbault, A.; Goyette, G.; Bourassa, C.; Gendron-Lepage, G.; Medjahed, H.; Richard, J.; Moreira, S.; Côté, M.; Finzi, A. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses 2022, 14, 144. https://doi.org/10.3390/v14010144

AMA Style

Chatterjee D, Tauzin A, Laumaea A, Gong SY, Bo Y, Guilbault A, Goyette G, Bourassa C, Gendron-Lepage G, Medjahed H, Richard J, Moreira S, Côté M, Finzi A. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses. 2022; 14(1):144. https://doi.org/10.3390/v14010144

Chicago/Turabian Style

Chatterjee, Debashree, Alexandra Tauzin, Annemarie Laumaea, Shang Y. Gong, Yuxia Bo, Aurélie Guilbault, Guillaume Goyette, Catherine Bourassa, Gabrielle Gendron-Lepage, Halima Medjahed, Jonathan Richard, Sandrine Moreira, Marceline Côté, and Andrés Finzi. 2022. "Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes" Viruses 14, no. 1: 144. https://doi.org/10.3390/v14010144

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI